MicroPort NeuroScientific

MicroPort NeuroScientific Net Margin

The Net Profit Margin of MicroPort NeuroScientific (2172.HK) as of Oct 27, 2026 is 23.34 %. In the previous year, Net Profit Margin was 33.37 % — a change of -30.04% (lower).

Net Margin

23.34 %

YoY

-30.04%

Last updated:

Net Profit Margin of MicroPort NeuroScientific is 2025 23.34 % . Net Profit Margin of MicroPort NeuroScientific was 2024 33.37 % . It decreases by -30.04% lower compared to the previous year.

For MicroPort NeuroScientific, the net margin of 23.3% is up versus 6.3% a few years ago.

The MicroPort NeuroScientific Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
25.57 CNY
Jan 1, 2020
20.41 CNY
Jan 1, 2021
6.31 CNY
Jan 1, 2022
-3.98 CNY
Jan 1, 2023
21.87 CNY
Jan 1, 2024
33.37 CNY
Jan 1, 2025
23.34 CNY
The MicroPort NeuroScientific Net Margin history
YEARNet MarginYoY
23.34 %-30.04%
33.37 %+52.59%
21.87 %-649.90%
-3.98 %-162.98%
6.31 %-69.06%
20.41 %-20.19%
25.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroPort NeuroScientific Stock analysis

What does MicroPort NeuroScientific do? MicroPort NeuroTech Ltd. generates revenue through the research, development, manufacturing, and sales of neuro-interventional medical devices. Its main products include embolization coils, flow-diverting stents, and stent grafts, targeting three key areas of neurovascular diseases: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company serves domestic and overseas markets, with its products primarily used by hospitals and healthcare providers for treating brain diseases. The firm's focus on neurovascular disease solutions drives its commercial strategy. The company operates under the brand MicroPort NeuroTech Ltd., which is part of the broader MicroPort group. It targets healthcare institutions globally, particularly those specializing in neurovascular care. The firm's product portfolio addresses critical treatment needs in neurovascular conditions, aligning with the growing demand for advanced medical devices in stroke management. Revenue streams are derived from direct sales of its medical devices to hospitals and clinics. MicroPort NeuroTech Ltd. focuses on the domestic and overseas markets, with its products designed for specific neurovascular applications. The company's revenue model relies on the sale of embolization coils, flow-diverting stents, and stent grafts to healthcare providers. These products are essential for treating conditions like hemorrhagic stroke and acute ischemic stroke, which are major causes of neurological disability. The firm's strategy emphasizes innovation in neuro-interventional solutions to capture market share in both local and international segments. MicroPort NeuroScientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroPort NeuroScientific stock

Net Profit Margin of MicroPort NeuroScientific is 23.34 % in 2025.

Net Profit Margin of MicroPort NeuroScientific changed from 33.37 % to 23.34 %, representing a -30.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin MicroPort NeuroScientific since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's MicroPort NeuroScientific with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — MicroPort NeuroScientific

All Key Metrics — MicroPort NeuroScientific